Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma
Pavlo Gilchuk(AstraZeneca (Japan)), James E. Crowe(Vanderbilt University Medical Center), Natalie Castellana, Kai Huang(Galveston College), Philipp A. Ilinykh(Houston Methodist), Larry Zeitlin(Mapp Biopharmaceutical (United States)), Ariadna Grinyo i Escuer(Integral Molecular (United States)), Jared Shaw(Pacific Northwest National Laboratory), Robin Bombardi(Vanderbilt University Medical Center), Edgar Davidson(Integral Molecular (United States)), Galit Alter(Ragon Institute of MGH, MIT and Harvard), Benjamin J. Doranz(Integral Molecular (United States)), Erica Ollmann Saphire(La Jolla Institute for Immunology), Elaine C. Chen(Vanderbilt University Medical Center), Stefano Bonissone, Adrian Guthals(Mapp Biopharmaceutical (United States)), Bronwyn M. Gunn(Washington State University), Jenny Liang(Integral Molecular (United States)), Alexander Bukreyev(Galveston College)
Cited by 12
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981